Summersalt Launches International Shipping
18.8.2021 14:01:00 EEST | Business Wire | Press release
Expanding Summersalt’s footprint globally, today the brand announces plans to introduce international shipping to over 180 countries in over 120 different currencies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210818005211/en/
Summersalt’s 2021 “Everybody is a Summersalt Body” campaign (Photo: Business Wire)
Summersalt will launch globally with shipping to Canada, the United Kingdom, India, Australia, Africa, Asia, Europe, South America and more. International customers will be offered a localized check out experience based on their respective currency, language and payment preferences, as well as guaranteed customs, duties and shipping calculations.
“Launching internationally is a logical next step as we strategically build upon Summersalt’s growth domestically and as demand for the brand accelerates worldwide,” said Lori Coulter, CEO, President and Co-founder of Summersalt. “As a digitally native brand, we are excited to expand our reach into new markets and to offer a seamless online shopping and returns experience to Summersalt’s international community.”
“Our customer is a global citizen who loves to travel and explore, and has been requesting Summersalt via every channel since launch day. We are thrilled to offer Summersalt around the world,” said Reshma Chattaram Chamberlin, Chief Digital Brand Officer and Co-founder of Summersalt.
Summersalt was founded on a mission to bring back the childlike joy of wearing a swimsuit by offering designer-quality swimwear at an affordable price. Summersalt offers not only swimwear, but loungewear, activewear, sweaters, pajamas, intimates and more in sizes 0-24.
International expansion plans come on the heels of Summersalt’s highly celebrated “Everybody is a Summersalt Body” campaign, which featured 24 incredible and diverse women, and was centered around joy and self-expression, aiming to empower women to feel good about themselves.
About Summersalt
Summersalt is a generation-defining apparel brand, providing wardrobe essentials for women who are going places. Summersalt launched in 2017 with swimwear made from recycled materials at a $95 price point — designer quality swimwear without the designer price tag. Since then, we’ve launched additional categories including loungewear, knitwear, sleepwear, intimates and activewear. Summersalt pieces are modern, sophisticated and fun, with an impeccable data-backed fit based on millions of measurements from over 10,000 women. In the few short years since our founding, Summersalt has built a loyal following of customers, influencers and celebrities, while garnering praise from leading fashion media including Vogue, Harper’s Bazaar, ELLE and InStyle. In 2019, Summersalt was included in CNBC’s Upstart 100 list and also named one of Fast Company’s Most Innovative Companies in 2020.
To learn more about Summersalt, visit summersalt.com or follow the brand on Instagram and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210818005211/en/
Contact information
Amanda Jacobs
Email: summersalt@azionepr.com
Phone: 646-490-2945
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom